我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

闭环刺激双腔起搏器防治血管迷走神经性晕厥的疗效观察

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2013年第1期
页码:
43-046,050
栏目:
临床研究
出版日期:
2013-02-25

文章信息/Info

Title:
Effect of dualchamber closedloop stimulation pacing in prevention of vasovagal syncope
作者:
萧钟波; 孟素荣; 邹云新; 赵冬华; 刘福强; 李 岩; 彭 健
(南方医科大学附属南方医院心内科，广东 广州 510515)
Author(s):
XIAO Zhongbo;  MENG Surong;  ZOU Yuxin;  ZHAO Donghua;  LIU Fuqiang;  LI Yan;  PENG Jian
(Department of Cardiology, Nanfang Hospital, Nanfang Medical University, Guangzhou 510515, Guangdong, China)
关键词:
闭环刺激; 心脏起搏; 晕厥; 血管迷走神经性
Keywords:
closeloop stimulation;  cardiac pacing;  syncope;  neurocardiogenic
分类号:
R364.14
DOI:
-
文献标识码:
A
摘要:
目的:观察植入闭环刺激双腔起搏器防治血管迷走神经性晕厥（VVS）的效果。方法： 将40例经直立倾斜试验确诊为VVS且近期多次发作的患者，分为起搏器组（18例）和药物治疗组（22例），所有患者均给予口服美托洛尔缓释片（475 mg，1次/d），起搏器组植入具有闭环刺激功能（CLS）的双腔起搏器，药物治疗组不做其他治疗，两组患者治疗3个月后复查直立倾斜试验并随访观察。结果： 起搏器组直立倾斜试验转阴率94%，药物治疗组直立倾斜试验转阴率29%，两组比较差异有统计学意义（P<001）。两组患者随访观察6～21(13±5)个月，起搏器组所有患者均未再发晕厥，2例有晕厥先兆，但症状较前明显减轻；药物治疗组9例再发晕厥，但发作次数较前减少。两组患者间晕厥复发率差异有统计学意义（P<001）。结论： 具有闭环刺激功能双腔起搏器能有效的防治血管迷走神经性晕厥。
Abstract:
AIM:To investigate the effect of dualchamber pacing in the prevention of vasovagal syncope. METHODS: Forty patients with vasovagal syncope who were confirmed by positive headup tilt table testing (HUTT) and had recent recurrent vasovagal syncope were randomly divided into pacemaker group (n=18) and pharmacotherapy group (n=22). All patients were orally administered metoprolol tablets (475 mg, qd). The patients in the pacemaker group were implanted with dualchamber closedloop stimulation (CLS) pacing, whereas patients in the pharmacotherapy group received no other treatment. Patients in both groups were examined again with HUTT 3 months after treatment and were followed up. RESULTS: The positive to negative rate of HUTT was 94% in the pacemaker group and 29% in the pharmacotherapy group, with statistically significant differences between groups (P<0001). During the followup (mean 13±5 months, range: 6-21 months), no patients in the pacemaker group had syncope, although two patients still had significantly alleviated syncope precursory symptoms and signs. Nine patients in the pharmacotherapy group had recurrent syncope, but with fewer attacks. A statistically significant difference was observed in the occurrence of syncope between groups (P<001). CONCLUSION: Dualchamber CLS pacing can prevent the occurrence of syncope in patients with vasovagal syncope.

参考文献/References

[1]方铭喜,蒋静涵.血管迷走性晕厥的治疗进展[J].国外医学·心血管疾病分册,1996,23(6):343-347.

[2]Fenton AM,Hammill SC,Rea RF,et al.Vasovagal syncope[J].Ann Intern Med,2000,133(9):714-725.

[3]中华心血管病杂志编委会倾斜试验对策专题组.倾斜试验用于诊断血管迷走性晕厥的建议[J]. 中华心血管病杂志,1998,26(5):325-327.

[4]Abboud FM.Neurocardiogenic syncope[J].N Engl J Med,1993,328(15):1117-1120.

[5]Theopistou A,Gatzoulis K,Economou E,et al.Biochemical changes involved in the mechanism of vasovagal syncope[J].Am J Cardiol,2001,88(4):376-381.

[6]Sheldon R,Connolly S,Rose S,et al.Prevention of Syncope Trial (POST):a randomized, placebocontrolled study of metoprolol in the prevention of vasovagal syncope[J].Circulation,2006, 113(9):1164-1170.

[7]Reybrouck T,Heidbuchel H,Van De Werf F,et al.Long term followup results of tilt training therapy in patients with recurrent neurocardiogenic syncope[J].Pacing Clin Electrophysiol,2002,25(10):1441-1446.

[8]Di Girolamo E,Di Iorio C,Leonzio L,et al.Usefulness of a tilt training program for the prevention of refractory neurocardiogenic syncope in adolescents:A controlled study[J].Circulation,1999,100(17):1798-1801.

[9]Connolly SJ,Sheldon R,Roberts RS,et al.The North American Vasovagal Pacemaker Study(VPS).A randomized trial of permanent cardiac pacing for the prevention of vasovagal syncope[J].J Am Coll Cardiol,1999,33(1):16-20.

[10]Sutton R,Brignole M,Menozzi C,et al.Dual chamber pacing in the treatment of neurally mediated tiltpositive cardioinhibitory syncope:pacemaker versus no therapy:a multicenter randomized study. The Vasovagal Syncope International Study(VASIS)Investigators[J].Circulation,2000, 102(3):294-299.

[11]Connolly SJ,Sheldon R,Thorpe KE,et al.Pacemaker therapy for prevention of syncope in patients with recurrent severe vasovagal syncope:Second Vasovagal Pacemaker Study(VPS II):a randomized trial[J].JAMA,2003,289(17):2224-2229.

[12]Moya A,Sutton R,Ammirati F,et al.Guidelines for the diagnosis and management of syncope(version 2009)[J].Eur Heart J,2009,30(21):2631-2671.

[13]Occhetta E,Bortnik M,Audoglio R,et al.Closed loop stimulation in prevention of vasovagal syncope.Inotropy Controlled Pacing in Vasovagal Syncope(INVASY):a multicentre randomized,single blind,controlled study[J].Europace,2004,6(6):538-547.

[14]Occhetta E,Bortnik M,Vassanelli C,et al.The DDDR closed loop stimulation for the prevention of vasovagal syncope: results from the INVASY prospective feasibility registry[J].Europace,2003,5(2):153-162.

[15]Bortnik M,Occhetta E,Dell’Era G,et al.Longterm follow up of DDDR closedloop cardiac pacing for the prevention of recurrent vasovagal syncope[J].J Cardiovasc Med(Hagerstown),2012,13(4):242-245.

[16]Palmisano P,Zaccaria M,Luzzi G,et al.Closedloop cardiac pacing vs. conventional dual chamber pacing with specialized sensing and pacing algorithms for syncope prevention in patients with refractory vasovagal syncope: results of a longterm followup[J].Europace,2012,14(7):1038-1043.

备注/Memo

备注/Memo:
收稿日期：2012-07-31.基金项目：广东省科技计划项目资助（2010B031600242） 通讯作者：彭健，主任医师，主要从事心脏电生理研究Email：jianpeng2003@126.com 作者简介：萧钟波，住院医师，硕士生Email：307523577@qq.com
更新日期/Last Update: 2013-03-20